IL159350A0 - Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury - Google Patents

Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury

Info

Publication number: IL159350A0
Authority: IL; Israel
Prior art keywords: pyridinic; spinal; brain; treatment; receptor antagonists
Prior art date: 2001-07-10

Application number

IL15935002A

Other languages

English (en)

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-10

Filing date

2002-07-03

Publication date

2004-06-01

2002-07-03 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-06-01 Publication of IL159350A0 publication Critical patent/IL159350A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL15935002A 2001-07-10 2002-07-03 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury IL159350A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01116812		2001-07-10
PCT/EP2002/007323 WO2003006016A2 (en)	2001-07-10	2002-07-03	Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury

Publications (1)

Publication Number	Publication Date
IL159350A0 true IL159350A0 (en)	2004-06-01

Family

ID=8178001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15935002A IL159350A0 (en)	2001-07-10	2002-07-03	Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury

Country Status (23)

Country	Link
US (3)	US20030083345A1 (es)
EP (2)	EP1621195A3 (es)
JP (1)	JP2004536119A (es)
KR (1)	KR100589106B1 (es)
CN (1)	CN100346789C (es)
AR (1)	AR037008A1 (es)
AU (1)	AU2002328837B2 (es)
BR (1)	BR0210893A (es)
CA (1)	CA2451566C (es)
GT (1)	GT200200143A (es)
HR (1)	HRP20031071A2 (es)
HU (1)	HUP0401210A3 (es)
IL (1)	IL159350A0 (es)
MX (1)	MXPA04000278A (es)
NO (1)	NO332847B1 (es)
NZ (1)	NZ530107A (es)
PA (1)	PA8549901A1 (es)
PE (1)	PE20030238A1 (es)
PL (1)	PL211246B1 (es)
RU (1)	RU2304435C2 (es)
UY (1)	UY27374A1 (es)
WO (1)	WO2003006016A2 (es)
ZA (1)	ZA200400138B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ523273A (en) *	2000-07-14	2004-08-27	F	N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
DE602004008631T2 (de) *	2003-07-03	2008-07-10	F. Hoffmann-La Roche Ag	Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
GB0410215D0 (en) *	2004-05-07	2004-06-09	Lescroart Pol	Nerve damage
CA2572645C (en)	2004-07-06	2011-01-18	F. Hoffmann-La Roche Ag	Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030600A1 (en) *	2004-08-06	2006-02-09	Patrick Schnider	Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2601935C (en) *	2005-02-22	2013-04-09	F. Hoffmann-La Roche Ag	Nk1 antagonists
WO2006089674A2 (en)	2005-02-25	2006-08-31	F.Hoffmann-La Roche Ag	Tablets with improved drug substance dispersibility
EP1863767B1 (en) *	2005-03-23	2009-03-11	F. Hoffmann-Roche AG	Metabolites for nk-i antagonists for emesis
KR101331768B1 (ko)	2005-11-08	2013-11-22	버텍스 파마슈티칼스 인코포레이티드	Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
DE102007018151A1 (de) *	2007-04-16	2008-10-23	Günenthal GmbH	Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
CA2686838C (en)	2007-05-09	2017-03-14	Vertex Pharmaceuticals Incorporated	Modulators of cftr
US20100184819A1 (en) *	2007-07-19	2010-07-22	Robert Vink	Method for reducing intracranial pressure
HRP20170241T2 (hr)	2007-12-07	2023-03-17	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
DK2639223T3 (en)	2007-12-07	2017-06-19	Vertex Pharma	Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids
NZ736561A (en)	2008-02-28	2018-02-23	Vertex Pharma	Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) *	2008-05-14	2008-06-18	Glaxo Wellcome Mfg Pte Ltd	Novel compounds
DK3150198T3 (da)	2010-04-07	2021-11-01	Vertex Pharma	Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
US20160129007A1 (en) *	2013-07-02	2016-05-12	Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)	Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV
RU2674653C2 (ru) *	2013-07-02	2018-12-12	Юстрэлиз Фармасьютикалз Лимитед (Трейдинг Эз Пресшура Нейро)	Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
US10729677B2 (en)	2013-07-02	2020-08-04	Eustralis Pharmaceutical Limited (Trading As Pressura Neuro)	Method for preventing and/or treating chronic traumatic encephalopathy-I
ES2671418T3 (es)	2013-11-08	2018-06-06	Kissei Pharmaceutical Co., Ltd.	Derivado de carboximetilpiperidina
RU2718044C2 (ru)	2013-11-12	2020-03-30	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
TWI649307B (zh)	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
HRP20211194T1 (hr)	2014-11-18	2021-10-29	Vertex Pharmaceuticals Inc.	Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
EP3746077A4 (en) *	2018-02-02	2021-10-27	Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro)	PARENTERAL FORMULATIONS AND THEIR USES
KR101970099B1 (ko) *	2018-02-07	2019-04-17	한국과학기술연구원	척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) *	2018-04-04	2019-07-31	한국과학기술연구원	뇌졸중의 예방 및 치료용 조성물
WO2021035289A1 (en) *	2019-08-23	2021-03-04	Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)	Therapeutic methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4745123A (en) *	1986-02-18	1988-05-17	Warner-Lambert Company	Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IL106142A (en) *	1992-06-29	1997-03-18	Merck & Co Inc	Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111002A (en) *	1993-09-22	1998-09-24	Glaxo Group Ltd	Piperidine derivatives their preparation and pharmaceutical compositions containing them
US6175013B1 (en) *	1994-06-10	2001-01-16	Eli Lilly And Company	Imidazolinyl tachykinin receptor antagonists
US5607947A (en) *	1995-02-21	1997-03-04	Eli Lilly And Company	Pyrrolidinyl tachykinin receptor antagonists
IL116249A (en) *	1994-12-12	2003-07-06	Pfizer	Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
TW382017B (en) *	1995-12-27	2000-02-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
US6214846B1 (en) *	1997-06-27	2001-04-10	Merck Sharp & Dohme Limited	Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US5972938A (en) *	1997-12-01	1999-10-26	Merck & Co., Inc.	Method for treating or preventing psychoimmunological disorders
JP4068305B2 (ja) *	1999-02-24	2008-03-26	エフ．ホフマン−ラロシュアーゲー	３−フェニルピリジン誘導体、およびそのｎｋ−１受容体拮抗薬としての用途
DK1394150T3 (da) *	1999-02-24	2011-03-21	Hoffmann La Roche	4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
US6303790B1 (en) *	1999-11-29	2001-10-16	Hoffman-La Roche Inc.	Process for the preparation of pyridine derivatives
SI1103545T1 (en) *	1999-11-29	2004-02-29	F. Hoffmann-La Roche Ag	2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
AUPQ514600A0 (en) *	2000-01-18	2000-02-10	James Cook University	Brain injury treatment

2002
- 2002-07-02 US US10/187,587 patent/US20030083345A1/en not_active Abandoned
- 2002-07-03 MX MXPA04000278A patent/MXPA04000278A/es active IP Right Grant
- 2002-07-03 IL IL15935002A patent/IL159350A0/xx unknown
- 2002-07-03 JP JP2003511822A patent/JP2004536119A/ja active Pending
- 2002-07-03 WO PCT/EP2002/007323 patent/WO2003006016A2/en not_active Ceased
- 2002-07-03 AU AU2002328837A patent/AU2002328837B2/en not_active Expired
- 2002-07-03 HU HU0401210A patent/HUP0401210A3/hu unknown
- 2002-07-03 HR HR20031071A patent/HRP20031071A2/xx not_active Application Discontinuation
- 2002-07-03 KR KR1020047000395A patent/KR100589106B1/ko not_active Expired - Lifetime
- 2002-07-03 EP EP05017203A patent/EP1621195A3/en not_active Withdrawn
- 2002-07-03 BR BR0210893-3A patent/BR0210893A/pt not_active IP Right Cessation
- 2002-07-03 CA CA2451566A patent/CA2451566C/en not_active Expired - Lifetime
- 2002-07-03 NZ NZ530107A patent/NZ530107A/en unknown
- 2002-07-03 RU RU2004102397/15A patent/RU2304435C2/ru active
- 2002-07-03 EP EP02764617A patent/EP1406618A2/en not_active Withdrawn
- 2002-07-03 PL PL369535A patent/PL211246B1/pl unknown
- 2002-07-03 CN CNB028135423A patent/CN100346789C/zh not_active Expired - Lifetime
- 2002-07-05 PA PA20028549901A patent/PA8549901A1/es unknown
- 2002-07-08 AR ARP020102546A patent/AR037008A1/es unknown
- 2002-07-08 PE PE2002000610A patent/PE20030238A1/es not_active Application Discontinuation
- 2002-07-09 GT GT200200143A patent/GT200200143A/es unknown
- 2002-07-09 UY UY27374A patent/UY27374A1/es not_active Application Discontinuation
2004
- 2004-01-07 NO NO20040057A patent/NO332847B1/no not_active IP Right Cessation
- 2004-01-08 ZA ZA2004/00138A patent/ZA200400138B/en unknown
2006
- 2006-07-05 US US11/481,216 patent/US20060247240A1/en not_active Abandoned
2010
- 2010-09-21 US US12/886,691 patent/US20110053954A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0401210A3 (en)	2011-07-28
KR20040029362A (ko)	2004-04-06
MXPA04000278A (es)	2004-05-04
RU2304435C2 (ru)	2007-08-20
US20060247240A1 (en)	2006-11-02
RU2004102397A (ru)	2005-04-20
CN100346789C (zh)	2007-11-07
HRP20031071A2 (en)	2004-06-30
AR037008A1 (es)	2004-10-20
US20030083345A1 (en)	2003-05-01
NZ530107A (en)	2006-01-27
CA2451566C (en)	2013-09-10
PA8549901A1 (es)	2003-01-24
KR100589106B1 (ko)	2006-06-14
NO332847B1 (no)	2013-01-21
BR0210893A (pt)	2004-06-22
GT200200143A (es)	2002-11-11
JP2004536119A (ja)	2004-12-02
PE20030238A1 (es)	2003-03-19
EP1621195A3 (en)	2010-01-06
EP1406618A2 (en)	2004-04-14
AU2002328837B2 (en)	2005-05-05
WO2003006016A3 (en)	2003-07-31
CA2451566A1 (en)	2003-01-23
ZA200400138B (en)	2005-06-29
UY27374A1 (es)	2003-03-31
EP1621195A2 (en)	2006-02-01
HUP0401210A2 (hu)	2004-10-28
NO20040057L (no)	2004-01-07
WO2003006016A2 (en)	2003-01-23
HK1068266A1 (en)	2005-04-29
PL211246B1 (pl)	2012-04-30
CN1523988A (zh)	2004-08-25
PL369535A1 (en)	2005-05-02
US20110053954A1 (en)	2011-03-03

Publication	Publication Date	Title
IL159350A0 (en)	2004-06-01	Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
AP2004002982A0 (en)	2004-03-31	Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
PL363907A1 (en)	2004-11-29	Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
IL150548A0 (en)	2003-02-12	Brain, spinal and nerve injury treatment
EP1420854A4 (en)	2011-02-23	TREATMENT OF NEUROPSYCHIATRIC DISORDERS BY NERVE STIMULATION NEAR THE DIAPHRAGM
AU2003249983A8 (en)	2004-02-09	Piperidines useful for the treatment of central nervous system disorders
PL373626A1 (en)	2005-09-05	Treatment for central nervous system disorders
IL176581A0 (en)	2006-10-31	Immunomodulatory compounds for the treatment of central nervous system disorders
GB0428462D0 (en)	2005-02-02	Spinal cord stimulation as treatment for functional bowel disorders
SI1474416T1 (sl)	2008-02-29	Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj
ZA200309977B (en)	2005-03-23	Arylamines for the treatment of conditions associated with GSK-3.
IL169091A0 (en)	2007-07-04	Benzazepine derivatives for the treatment of neurological disorders
PT2260850T (pt)	2018-10-24	Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
IL158631A0 (en)	2004-05-12	4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
ZA200402514B (en)	2005-01-24	4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
IL157145A0 (en)	2004-02-08	Use of dc23 antagonists for the treatment of neoplastic disorders
PL368556A1 (en)	2005-04-04	Methods for treating or preventing skin disorders using cd2-binding agents
TWI319765B (en)	2010-01-21	1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
AU2003290059A8 (en)	2004-07-09	Use of cd137 antagonists for the treatment of tumors
IL158704A0 (en)	2004-05-12	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL162475A0 (en)	2005-11-20	Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
IL158703A0 (en)	2004-05-12	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
ZA200501288B (en)	2005-09-05	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
IL158632A0 (en)	2004-05-12	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158695A0 (en)	2004-05-12	4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders